Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]) Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical) - Forecast to 2031

Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]) Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical) - Forecast to 2031

Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]), Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical)—Global Forecast to 2031.

The Europe cancer diagnostics market is projected to reach $12.21 billion by 2031, at a CAGR of 5.6% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report analyzes key industry drivers, restraints, challenges, and opportunities. The growth of this market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, and increasing investments and funding for cancer research. Additionally, the supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market.

However, the high cost of imaging systems restrains the growth of this market. Additionally, the lack of skilled professionals and insufficiencies in the implementation of cancer screening programs pose a significant challenge to the market's growth.

Among the products, in 2024, the IVD segment is expected to account for the largest share of the Europe cancer diagnostics market. IVD instruments provide precise, reliable screening and diagnostic testing through simple workflows and integrated software. Furthermore, IVD consumables assist healthcare providers in obtaining vital information regarding genetic abnormalities, tumor markers, and other diagnostic indicators to monitor disease development, guide treatment decisions, and assess therapy responses in cancer patients. The large market share of this segment is attributed to the advancements in IVD technology, the commercial availability of a diverse range of IVD reagents & consumables for the diagnosis of cancer, and the recurring use of IVD consumables.

Among the cancer types, in 2024, the breast cancer segment is expected to account for the largest share of the Europe cancer diagnostics market. The increase in breast cancer cases, increasing healthcare expenditure, and inclusion of certain advanced technologies such as NGS in the reimbursement have propelled the demand for cancer diagnostics for breast cancer. Additionally, government initiatives promoting breast cancer awareness regarding diagnosis and treatment boost breast cancer diagnosis. For instance, in October 2023, Galderma SA (Switzerland) launched a new breast cancer campaign called ‘Facing Breast Cancer Together’, this campaign focuses on providing support and education about breast cancer awareness. Galderma has partnered with the National Breast Cancer Foundation (NBCF) to promote breast cancer awareness.

Among the end users, in 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the Europe cancer diagnostics market. The large market share of this segment is attributed to the increasing cancer cases, the higher purchasing power of hospitals and diagnostic laboratories, well-equipped operating & diagnostic rooms, the presence of highly skilled healthcare professionals, ease in accessibility, better health coverage for hospital-based healthcare services from various private & group insurance plans, and the increasing number of hospitals and expansion of diagnostic laboratories.

An in-depth analysis of the Europe cancer diagnostics market provides detailed qualitative and quantitative insights into major countries, namely Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe. In 2023, Germany is estimated to account for the largest share of the Europe cancer diagnostics market. The market growth in Germany is attributed to the increasing prevalence of cancer, the high adoption of advanced technologies, the established healthcare systems, rising healthcare expenditures, increasing investments and funding for cancer research, and initiatives to raise awareness about cancer diagnosis.

Some of the key players operating in the Europe Cancer Diagnostics market report are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic, Inc. (U.S.).

Scope of the Report:

Europe Cancer Diagnostics Market Size & Trend Analysis—by Product

In Vitro Diagnostics
IVD Consumables
Kits & Assays
Reagents
IVD Instruments
Polymerase Chain Reaction (PCR) Systems
Microarray Readers
Immunoassay Analyzers
Sequencers
Other IVD Instruments
IVD Software & Services

(Other IVD instruments include in-situ hybridization, hematology analyzers, and clinical chemistry analyzers)

Diagnostic Imaging

Imaging Instruments
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Mammography
Ultrasound
Other Imaging Instruments

(Other imaging instruments include Positron Emission Tomography (PET) and X-ray)

Imaging Consumables
Contrast Agents
Syringes and Injectors
Contrast Delivery Systems
Skin Markers
Phantoms
Other Imaging Consumables

(Other imaging consumables include films, gels, transducers, and probes, among others)
Imaging Software and Services

Europe Cancer Diagnostics Market Size & Trend Analysis—by Cancer Type

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Other Cancer Type

Note: Other cancer types include leukemia, lymphoma, stomach, ovarian, melanoma, kidney, and cervical cancers.

Europe Cancer Diagnostics Market Size & Trend Analysis—by End User

Hospital & Diagnostics Laboratories
Diagnostic Imaging Centers
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes

Europe Cancer Diagnostics Market Size & Trend Analysis—by Country

Germany
France
Italy
U.K.
Spain
Switzerland
Netherlands
Rest of Europe

Europe Cancer Diagnostics Market - Report Summary

Report Metrics	Details
Years Considered	2022 - 2031
Base Year	2023
Forecast Period	2024-2031
Page Count	209
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Product, Cancer Type, End User, and Geography
Regions Covered	Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe)
Key Companies Mentioned	F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic Inc. (U.S).

FAQs About the Report

What is the focus of the Europe cancer diagnostics market?

The Europe cancer diagnostics market covers the market sizes & forecasts of offering, including product, cancer type, and end user. The Europe cancer diagnostics market studied in this report involves the value analysis of various segments and sub-segments of the Europe cancer diagnostics market at country levels.

What is the value of revenue generated from sales of cancer diagnostic products in Europe? At what rate is their demand expected to grow for the next 5-7 years?

The Europe cancer diagnostics market is projected to reach $12.21 billion by 2031, at a CAGR of 5.6% during the forecast period.

Which Product segment held the major share of the market in 2024?

In 2024, the In Vitro Diagnostics segment is expected to account for the largest share of the Europe cancer diagnostics market.

Which Cancer Type segment is projected to create more traction in the Europe cancer diagnostics market?

The breast cancer segment is projected to create more traction in the Europe cancer diagnostics market.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the Europe cancer diagnostics market?

The Europe cancer diagnostics market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, and increasing investments and funding for cancer research. Furthermore, supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market.

Who are the major players operating in the Europe cancer diagnostics market?

The key players operating in the Europe cancer diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic Inc. (U.S).

Which countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

France, Germany, and the U.K. are projected to offer significant growth opportunities for the vendors in this market due to factors such as increasing cancer incidence, supporting government initiatives, rising healthcare expenditure, growing demand for precision oncology, and growing R&D investments for cancer.